The number of novel, pivotal-stage projects in big pharma pipelines has plunged – just as Covid-19 put the brakes on deal making.
Neurocrine Biosciences' latest collaboration, with Takeda, gives it three more high-risk bets in neuroscience.
Last month the FDA greenlit four oncology approvals early and the first GnRH antagonist in uterine fibroids.
Pivotal ulcerative colitis data on etrolizumab, a dual-action anti-integrin antibody, are due soon, and Roche has Takeda’s Entyvio in its sights.
New consensus forecasts stretching out to 2026 see Roche easily retaining its crown as the world’s biggest drugmaker, while Bristol-Myers Squibb climbs the rankings.
The coronavirus pandemic notwithstanding, Curadev snares its second Sting partner.
The company’s Eysuvis looks set to be approved for dry eye disease, but meeting expectations in this tough market will not be easy.
The industry has a duty to develop Covid-19 antivirals and vaccines, but the nature of clinical trials means that lower-profile measures must take precedence.
The deal between Sangamo and Biogen marks another endorsement of a gene-editing technology that many had written off years ago.